Compare Ascendis Pharma A/S (ASND) vs CubeSmart (CUBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs CubeSmart — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while CubeSmart trades at $40.86 (market cap $9.23B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and CubeSmart pays a 5.17% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CUBE | |
|---|---|---|
Market Cap | $16.78B | $9.23B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $42.50 |
52-Week Low | $189.74 | $35.36 |
Enterprise Value | $17.15B | $12.76B |
Dividend Yield | — | 5.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
CubeSmart (CUBE) trades at $41.77, down slightly (-0.19%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $43.86 offering modest upside. The REIT has demonstrated consistent earnings beats in recent quarters and maintains strong profitability with a 29.41% net income margin. Recent news highlights improving operational trends, including higher occupancy and a raised full-year revenue outlook for 2026, suggesting a potential inflection point.
The outlook is cautiously optimistic, supported by operational momentum and a solid 5% dividend yield. Key risks include a high debt load, with long-term debt of $2.99 billion, and sensitivity to interest rate changes. While analyst sentiment is mixed (44.83% Buy, 51.72% Hold), the stock presents a value opportunity if operational improvements continue, though investors should weigh the debt burden against the stable income profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
